B型肝炎病毒(hepatitis B virus，HBV)感染是導致肝臟病變的隱形殺手，長久以來危及人們的健康。B型肝炎病毒基因型分為(A~H)8型，不同基因型的病毒，會導致病毒在基因、結構、以及臨床表現上的差異，此外病毒序列的變異對感染者於病程趨向之影響，亦是B型肝炎相關研究者積極探討之問題。
因此本研究將應用資料探勘(Data Mining)技術，由病毒胺基酸序列的表現來辨別出(A~H)8種基因型，並且指出與臨床因子(如：基因型、病毒量高低、血清轉換與否等…)相關之胺基酸序列位置，此外，並設計一統計分析系統，計算大量病毒序列的突變率以及根據各種不同分組條件來進行統計分析。
研究結果顯示由P基因第73位置、104位置以及199位置，即可將NCBI資料庫358株病毒序列，分辨出 (A~H)8個基因型，其準確率達100%。並且由病人抽血第一時間點的病毒胺基酸序列，歸納出可判定病人是否有走入血清轉換的或已達血清轉換的趨勢之準則。也根據不同時間點病毒的突變率，指出病毒在病程中突變演化的動力假說。

The hepatitis B virus infection is the invisible killer of pathological changes of liver, and endangered people''s health for a long time. The hepatitis virus genotype has 8 different types (A to H), and genotypes have different genes, and structures, and induces different results. In addition, the influence of the variation of the virus sequence is also our study in this thesis.
This research will apply data mining technique to distinguish the genotypes from the amino acids sequence of the virus, and point out the relation between amino acids sequence position and the clinical results. In addition, we designed a statistical analysis software for calculating mutation rate from the mass virus sequences and did some statistical analyses on some conditions predefined by users.
Analysis results show that we can distinguish 8 genotypes according to the 73th, 104th and 199th positions of the P gene among 358 virus sequences in the NCBI database, and its correct rate reached 100%. We can also predict the HBeAg of patients to be seroconversion or not. According to amino acids sequence of virus in the first sampled blood, we can predict the trend of HBeAg seroconversion. Finally, we leads the motive hypothesis that the evolution of the virus in disease exits the high relationship with the mutation rate in different time periods.

中文摘要
英文摘要
致謝
目錄
表目錄
圖目錄
第一章 緒論 1
第一節 研究動機 1
第二節 研究目的 3
第三節 名詞釋義與說明 4
第四節 研究流程 5
第二章 文獻探討 7
第一節 B型肝炎病毒 7
2.1.1 B型肝炎病毒簡介 7
2.1.2 慢性B型肝炎臨床特色以及用藥簡介 10
2.1.3 HBV序列突變與慢性B型肝炎病程的相關性 12
第二節 資料探勘技術 14
2.2.1 資料探勘的定義 14
2.2.2 關聯分析 15
2.2.3 生物資訊軟體介紹 18
第三章 研究方法 20
第一節 B型肝炎病毒序列突變位置相關性之探勘 20
3.1.1 研究資料處理 20
3.1.2運作流程 20
3.1.3 探勘之資料格式設計 25
3.1.4 探勘操作流程 28
第二節 B型肝炎病毒動態與病毒各基因片段突變率相關性之統計分析 36
3.2.1 統計分析系統 36
3.2.2 系統實作及操作說明 37
第四章 結果分析與討論 43
第一節 B型肝炎病毒各基因型胺基酸準則的特色 43
第二節 關聯規則與臨床因子之相關性 51
4.2.1 B型肝炎病毒動態分組 51
4.2.2 關聯規則與血清轉換與否之相關性 53
4.2.3關聯規則與病毒基因型之相關性 57
4.2.4關聯規則與病毒量高低之相關性 58
4.2.5 B型肝炎病毒動態分組與病毒突變率的相關性 61
4.2.6 B型肝炎病毒動態組別與病毒突變特異點的相關性63
第五章 結論與未來方向 65
參考文獻 67
一、英文部份 67
二、中文部份 71

Agrawal, R., Imielinski, T., & Swami, A.(1993). Mining Association Rules between Sets of Item in Large Database. Proceedings of the ACM-SIGMOD Conference On the Management of Data, 207-216.
Agrawal, R., & Srikant, R. (1994). Fast Algorithm for Mining Assoication Rule in Large Databases. Proceedings of Conference On Very Large Data Base,478-499.
Atkins, M., Hunt, CM., Brown, N., Gray, F., Sanathanan, L., Woessner, M., et al. (1998). Clinical significance of YMDD mutant Hepatitis B virus in large cohort of lamivudine-treated hepatitis B patient. Hepatology, 28, 319A.
Bartholomeusz, A., & Schaefer S. (2004). Hepatitis B virus genotypes: comparison of genotyping methods. Rev Med Virol, 14(1), 3-16.
Chayama, K., Suzuki, Y., Kobayashi, M., Kobayashi, A., Tsubota, A. & Hashimoto, M. (1998). Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 27, 1711–6.
Farrell, G. C. (2000). Clinical potential of emerging new agents in hepatitis B. Drugs,60(4), 701-10.
Frank, E. & Witten, H.(1999).Data Mining：Practical Machine Learning Tools and Technigues with Java Implementation.San Francisco：Morgan Kaufmann.
Han, J., & Kamber, M. (2001). Data Mining:Concepts and Techiniques.
USA: Morgan Kaufmann.
Kidd-Ljunggren, K., Miyakawa, Y., & Kidd AH. (2002). genetic variability in hepatitis B viruses. Journal of General Virology, 83, 12667-1280.
Kramvis, A., Weitzmann, L., Owiredu, WK., & Kew, MC. (2002). Analysis of the complete genome of subgroup A’ hepatitis B virus isolates from South Africa. J Gen Virol, 83, 835–839.
Lai, C. L., Rosmawati, M., & Lao, J.(2002). Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology, 123(6), 1831-8.
Liaw, Y. F. (2002). Therapy of chronic hepatitis B: current challenges and opportunities. J Viral Hepat, 9(6), 393-9.
Liaw, Y. F. (2002). Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. J Gastroenterol Hepatol, 17(S3), S333-S337.
Lin, C. L., Liao L. Y., Wang C. S., Chen P. J., Lai M. Y., Chen D. S., et al.(2005). Basal core-promoter mutant of hepatitis B virus and progression of liver disease in hepatitis B e antigen-negative chronic hepatitis B. Liver International, 25, 564–570.
Marcellin, P. (2002). Advances in therapy for chronic hepatitis B. Semin Liver Dis,1(S1), 33-6.
Naito, H., Hayashi, S., & Abe, K.(2001). Rapid and Specific Genotyping System for Hepatitis B Virus Corresponding to Six Major Genotypes by PCR Using Type-Specific Primers. JCM, 362-364.
Nowak, R. (1995). Entering the postgenome era. Science, 270, 368-371.
Papatheodoridis, G. V., Dimou, E., & Papadimitropoulos, V.(2002). Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. Am J Gastroenterol, 97(7), 1618-28.
Perrillo, R. P. (1994). The management of chronic hepatitis B. Am J Med, 96(1A),34S-39S.
Perrillo, R. P. (1993). Interferon in the management of chronic hepatitis B. Dig Dis Sci, 38(4), 577-93.
Perrillo, R, Schiff, E, & Yoshida, E.(2000). Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology, 32(1), 129-34.
Schalm, S., De Man R., & Janssen H. (2002). Combination and newer therapies for chronic hepatitis B. J Gastroenterol Hepatol, 17( S3), S338-S341.
Sugauchi, F., Orito, E., Kato, H., Suzuki, S., Kawakita, S., Sakamoto, Y., et al. (2003). Genotype, serotype, and phylogenetic characterization of the complete genome sequence of hepatitis B virus isolates from Malawian chronic carriers of the virus. J Med Virol, 69, 33–40.
Thompson, J. D., Gibson, T. J., Plewniak, F., Jeanmougin, F., Higgins, D. G. (1997). The ClustalX windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res, 24, 4876-4882.
Toivonen H. (1996). Sampling Large Database for association Rule. Proceeing of Conference On Very Large Data Base, 134-145.
Wolters, L. M., & Hansen, B.E. (2002). Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J Hepatol, 37(1),137-44.
Xiong, X., Yang, H., Westland, CE., Zou R., & Gibbs CS.(2000). In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance. Hepatology, 31(1), 219-24.
周文賢(民國86)。統計學。臺北市：智勝文化事業。
孔燁曼(民國88)。基礎生物統計學。臺北市：學富。
巴奧里拉(民國89)。基礎分子生物學。臺北市：合記。